Scientists have pinpointed a genetic mechanism that fuels fatty liver disease and found that a common, inexpensive vitamin can suppress it, opening a potential new avenue for treatment.
The breakthrough centers on microRNA-93, a genetic regulator that researchers identified as a primary driver of the condition. When present at elevated levels, this microRNA accelerates fat accumulation in liver tissue. The finding matters because fatty liver disease—both the alcohol-related and non-alcohol-related forms—affects hundreds of millions of people worldwide and has few therapeutic options.
The researchers discovered that vitamin B3, also known as niacin, effectively blocks microRNA-93's activity. The vitamin is already widely used, inexpensive, and considered safe for most people, making it an attractive candidate for clinical development.
If the mechanism holds up in human trials, B3 could offer patients a straightforward intervention without the side effects or costs associated with many experimental drugs. The vitamin is available over the counter and has a long history of medical use, which could potentially accelerate its path to clinical approval as a fatty liver treatment.
The research represents a shift toward understanding how genetic factors drive liver disease progression. Rather than treating symptoms alone, targeting the underlying microRNA offers a more direct approach to preventing fat buildup.
While the initial findings are encouraging, researchers emphasize that further testing is needed to confirm the results in human patients and determine optimal dosing. The work does suggest, however, that solutions to serious health problems sometimes lie within existing, accessible treatments that have simply not been tested for particular conditions before.
Comments